Ring box protein-1 is associated with a poor prognosis and tumor progression in esophageal cancer.

• Material Type: 博士論文
• Title: Ring box protein-1 is associated with a poor prognosis and tumor progression in esophageal cancer.
• Author/Editor: Kunishige, Tomohiro; Migita, Kazuhiro; Matsumoto, Sohei; Wakatsuki, Kohei; Nakade, Hiroshi; Miyao, Shintaro; Kuniyasu, Hiroki; Sho, Masayuki
• Author Heading: Kunishige, Tomohiro; Migita, Kazuhiro; Matsumoto, Sohei; Wakatsuki, Kohei; Nakade, Hiroshi; Miyao, Shintaro; Kuniyasu, Hiroki; Sho, Masayuki
• Publication, Distribution, etc.: Spandidos Publications
• Publication Date: 2020-09
• Publication Date (W3CDTF): 2020-09
• Alternative Title: Ring box protein-1 は食道癌の予後不良因子であり、腫瘍の進行と関連している
• Periodical title: Oncology letters
• No. or year of volume/issue: 20 3
• Volume: 20
• Issue: 3
• Pages: 2919-2927
• ISSN (Periodical Title): ISSN : 1792-1074
• Degree grantor/type: 奈良県立医科大学
• Date Granted: 2020-12-24
• Dissertation Number: 乙第1480号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Subject Heading: ring box protein-1; prognostic factor; proliferation; chemotherapy; esophageal cancer
• Target Audience: 一般
• Note (General): type:Thesis; Ring box protein-1 (RBX1) is an essential component of the S-phase kinase-associated protein, Cullin and F-box containing ubiquitin ligases. Overexpression of RBX1 has been reported in several cancer types; however, little is known regarding the prognostic value and role of RBX1 in esophageal cancer. The present study examined 120 patients with esophageal cancer (EC) who underwent curative esophagectomy and 61 patients with EC who underwent neoadjuvant combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil (5-FU; DCF) using immunohistochemistry. All specimens were classified into two groups according to the percentage of RBX1-positive tumor cells. In addition, the impact of RBX1 expression on cancer cell proliferation was analyzed in vitro using a small interfering RNA silencing technique. RBX1 expression levels showed significant differences according to tumor size (P<0.001), tumor depth (P=0.002), lymph node metastasis (P=0.004), pathological stage (P=0.001), lymphatic invasion (P=0.001) and venous invasion (P=0.001). The overall survival (OS) rate in the RBX1 high expression group was significantly lower compared with that in the low group (P=0.004). Multivariate analysis demonstrated that RBX1 status was an independent prognostic factor. RBX1 gene silencing inhibited the proliferation of human EC cells and enhanced the antitumor effect of 5-FU. Among patients who underwent neoadjuvant DCF therapy, the RBX1 high expression group had a significantly lower OS rate compared with that of the RBX1-low group (P<0.001). In conclusion, RBX1 has notable prognostic value, and RBX1 may serve an important function in the tumor progression of EC.; 博士（医学）・乙第1480号・令和2年12月24日; Copyright: © Kunishigeet al. This is an open access article distributed under theterms of CreativeCommons Attribution License(https://creativecommons.org/licenses/by-nc-nd/4.0/).; identifier:Oncology letters Vol.20 No.3 p.2919-2927 (2020 Sep); identifier:17921074; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/3825; identifier:Oncology letters, 20(3): 2919-2927
• Access Restrictions: インターネット公開
• Related Material (DOI): 10.3892/ol.2020.11840
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU

Table of Contents

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3825/1/01%e4%b9%991480%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3825/2/02%e4%b9%991480%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3825/3/03%e4%b9%991480%e6%9c%ac%e6%96%87.pdf fulltext